Evidence map›Paper›PMID 35907607›Full record

ArticleBioorganic & medicinal chemistry letters2022

Conversion of oxadiazolo[3,4-b]pyrazines to imidazo[4,5-b]pyrazines via a tandem reduction-cyclization sequence generates new mitochondrial uncouplers.

Yumin Dai, José A Santiago-Rivera, Stefan Hargett, Joseph M Salamoun, Kyle L Hoehn, Webster L Santos

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yumin DaiDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, United States.
José A Santiago-RiveraDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, United States.
Stefan HargettDepartments of Pharmacology and Medicine, University of Virginia, Charlottesville, VA 22908, United States.
Joseph M SalamounDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, United States.
Kyle L HoehnDepartments of Pharmacology and Medicine, University of Virginia, Charlottesville, VA 22908, United States; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2033, Australia.
Webster L SantosDepartment of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, United States. Electronic address: santosw@vt.edu.

Funding

VT Initiative for Maximizing Student DiversityR25GM072767 · NIGMS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI SMITH, EDWARD J · 2007 to 2021
$6.9M
Therapeutic Mitochondrial UncouplersR01DK128612 · NIDDK · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI HOEHN, KYLE LEE, SANTOS, WEBSTER L · 2021 to 2024
$2.2M
NIDDK NIH HHS R01 DK128612NIGMS NIH HHS R25 GM072767
6 · The paper itself

Abstract

We report new mitochondrial uncouplers derived from the conversion of [1,2,5]oxadiazolo[3,4-b]pyrazines to 1H-imidazo[4,5-b]pyrazines. The in situ Fe-mediated reduction of the oxadiazole fragment followed by cyclization gave access to imidazopyrazines in moderate to good yields. A selection of orthoesters also allowed functionalization on the 2-position of the imidazole ring. This method afforded a variety of imidazopyrazine derivatives with varying substitution on the 2, 5 and 6 positions. Our studies suggest that both a 2-trifluoromethyl group and N-methylation are crucial for mitochondrial uncoupling capacity.

Indexed as

MitochondriaPyrazinesCyclizationOxadiazolesOxadiazolesPyrazines

Identifiers

PMID35907607
PMCPMC10966457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.